Stopped: COVID-19
Hyperoxygenation for resuscitation of abnormal fetal heart rate tracings has been routine obstetric practice. However, there have not been any studies to support this practice. Recent literature have either found no associated benefit to intrapartum maternal oxygen administration, or in a number of studies demonstrated higher risk of neonatal complications. Despite these studies, the evidences have not been adequate to change the clinical practice because the majority of these studies either focused on biological differences rather than clinical outcomes data or were retrospective rather than randomized trials. Therefore, the investigators propose a large single center randomized clinical trial to determine the effects of maternal hyperoxygenation therapy for the treatment of fetal heart rate tracing abnormalities.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Perinatal death
Timeframe: Delivery through discharge and average of 1 week
Respiratory distress syndrome
Timeframe: Delivery through 72 hrs of life
Low 5 minute Apgar score
Timeframe: At 5 minute of life
Hypoxic-ischemic encephalopathy
Timeframe: Delivery through discharge and average of 1 week
Neonatal seizure
Timeframe: Delivery through discharge and average of 1 week
Meconium aspiration syndrome
Timeframe: Delivery through discharge and average of 1 week
Intracranial hemorrhage
Timeframe: Delivery through discharge and average of 1 week
Neonatal hypotension
Timeframe: Delivery through discharge and average of 1 week